Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities
New Target Added to Ongoing Collaboration with Bristol Myers Squibb
Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases
New Collaboration and Software Agreement with
“We are very proud of our achievements in 2022 across all areas of our business. We continued to enhance the capabilities of our platform, we made great progress in our existing collaborations and added new ones, and we advanced our first internal product candidate, SGR-1505, to the clinic. Our successes further validate the ability of our physics-based methods to accelerate discovery of novel drug candidates for important targets with best-in-class potential,” stated
Today Schrödinger announced several new developments, including the following:
- Schrödinger and Bristol Myers Squibb amended their discovery, development and commercialization collaboration to include a new discovery program in neurology. Schrödinger received an additional upfront payment for the new program and is eligible to receive discovery, development and commercialization milestones, as well as royalties on net sales, similar to the terms of the original agreement.
- Schrödinger reported a new program targeting LRRK2, a genetically validated target with therapeutic potential for the treatment of Parkinson’s disease. In 2022, Schrödinger generated cryo-electron microscopy structures of LRRK2 which is helping to accelerate the identification of novel LRRK2 inhibitors. Schrödinger expects to select a development candidate for this program in 2024.
Otsuka Pharmaceutical Co., Ltd., a leading healthcare company in Japan, together with Otsuka’s subsidiary Astex Pharmaceuticals, announced an innovative multi-part agreement that includes a collaboration to discover molecules for an emerging CNS disease target, as well as a knowledge-transfer program and expanded licensing agreement for Schrödinger’s platform for Otsuka’s new drug discovery facility. Under the terms of the drug discovery portion of the agreement, Schrödinger will be responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities. Schrödinger received an upfront payment and will be eligible to receive discovery, development and regulatory milestones, as well as tiered royalties on net sales of any products emerging from the drug discovery collaboration in all markets.
Today Schrödinger also highlighted several 2022 achievements, including the following:
- Received FDA clearance for the investigational new drug (IND) application for SGR-1505, a MALT1 inhibitor, and opened enrollment for the Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies
Presented new preclinical data on its potent and selective CDC7 inhibitor, SGR-2921, at the
American Society of Hematology(ASH) 64th Annual Meeting
Presented preclinical data from its Wee1 program at the
American Association of Cancer ResearchAnnual Meeting
- Entered into an agreement with Eli Lilly and Company for the discovery and optimization of small molecule compounds addressing an undisclosed target
- Initiated six new internal programs in oncology and immunology
Progress at Companies with Equity Ownership by Schrödinger
- In December, Nimbus announced a definitive agreement with Takeda under which Takeda agreed to acquire Nimbus’s TYK2 inhibitor, NDI-034858, which is being evaluated for the treatment of multiple autoimmune diseases following positive results from the Phase 2b clinical trial in psoriasis. Schrödinger has an equity stake in Nimbus and subject to certain conditions, including the approval of Nimbus’s board of directors, expects to receive a cash distribution from Nimbus following the closing of the transaction, which is expected in the first half of 2023 and is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976. A recent post on Schrödinger’s blog, Extrapolations, describes how NDI-034858 was developed using Schrödinger’s physics-based computational platform.
- Morphic Therapeutic made significant progress advancing MORF-057, an oral α4β7 integrin inhibitor, for the treatment of ulcerative colitis (UC), including reporting positive Phase 1 clinical data and initiating a Phase 2b study in patients with moderate-to-severe UC.
- In December, Ajax Therapeutics presented positive preclinical data on AJ1-10502, a next generation Type II JAK2 inhibitor, at the ASH Annual Meeting. The preclinical data showed that AJ1-10502 demonstrated enhanced selectivity and improved efficacy compared to ruxolitinib in multiple disease models of myeloproliferative neoplasms.
- Schrödinger scientists continued to make significant advances to the company’s platform. This includes expanding the number and types of targets for which the platform is enabled, increasing hit rates in hit discovery, and enhancing the predictive accuracy of key drug-like properties of molecules. Schrödinger scientists were authors on 22 publications in peer-reviewed life sciences and material science journals, including a co-authored manuscript describing how Schrödinger’s predictive computational methods accelerated Nimbus’s discovery of potent, selective TYK2 inhibitors.
Geoffrey Porges, MBBS., as chief financial officer to lead all aspects of the company’s financial operations, investor relations and corporate affairs activities, as well as oversee business development and strategic planning for the company’s proprietary pharmaceuticals and biopharmaceutical collaborations.
Entered into a three-year collaboration with
Eonix LLCto accelerate the discovery and design of materials for safer, energy dense lithium ion batteries.
Acquired and integrated
XTAL BioStructures, Inc., enabling Schrödinger to pursue scientific advancements in the field of structural biology and enhance its ability to produce high quality target structures for drug discovery.
2023 Strategic Priorities
Today Schrödinger outlined the following strategic priorities for 2023:
- Complete dose-escalation portion of the Phase 1 clinical trial of SGR-1505
- Submit IND for SGR-2921 and initiate Phase 1 dose-escalation trial
- Select Wee1 inhibitor development candidate and initiate IND-enabling studies
- Advance LRRK2 program toward development candidate status
- Enter into at least one new multi-target drug discovery collaboration
- Advance and disclose additional unpartnered proprietary drug development programs
- Publish new preclinical data from wholly-owned programs in peer-reviewed forums
- Leverage new structural biology capabilities and advance computational technologies to enable new targets for drug discovery
- Advance and publish validation of technology enabling discovery of novel biologics
- Enter into at least one new materials science collaboration
Schrödinger will report its fourth quarter and full-year financial results and provide 2023 financial guidance on
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has approximately 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including but not limited to those regarding the potential advantages of our computational platform, our research and development efforts for our proprietary drug discovery programs and our platform, the initiation, timing, progress, and results of our proprietary drug discovery programs and the drug discovery programs of our collaborators, the clinical potential and favorable properties of our CDC7, MALT1, and Wee1 inhibitors, including SGR-1505 and SGR-2921, and other compounds discovered with our platform, the timing of potential IND submissions as well as initiation of clinical trials for our proprietary drug discovery programs, the clinical potential and favorable properties of our collaborators’ product candidates, including
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005253/en/
Source: Schrödinger, Inc.